Since hyperpalmitoylation of known GluA1 palmitoylation sites can alter seizure susceptibility [52], our discovery of a novel palmitoylation site that is critical for AMPAR function (C323, Fig 3E) opens avenues for investigation of the molecular basis of epilepsy in CLN1. Here, PPT1 is linked to epilepsy.